Supplementary Figures – Peripheral blood eosinophil count is associated with response to chemo-immunotherapy in metastatic TNBC

Supplementary Figure 1: Peripheral blood Eosinophil count (PBEC) in patients enrolled in Paclitaxel/Durvalumab Trial including (A) patients with confirmed complete or partial response (n=5), (B) patients with unconfirmed complete or partial response (n=3), (C) non-responders (with stable disease or progressive disease) (n=6), and (D) patients who progressed during the first priming paclitaxel alone cycle (n=5). Tb=beginning of treatment, Ts=treatment stopped, Tcont=treatment continues.

Supplementary Figure 2: Correlation of baseline monocyte count in peripheral blood before receiving the Paclitaxel/Durvalumab therapy and survival. Kaplan–Meier survival curves showing progression-free survival (PFS) and overall survival (OS) in patients based on baseline monocytes (> 450 cell/mm3) who received the Paclitaxel and Durvalumab combination therapy (Top) and in all the ITT patients (Bottom).

Supplementary Figure 3: Correlation of baseline neutrophil to lymphocyte (NLR) or platelet to lymphocyte (PLR) count and survival. Kaplan–Meier survival curves showing progression-free survival (PFS) and overall survival (OS) in patients based on baseline NLR or PLR who received the Paclitaxel and Durvalumab combination therapy (A) and in all the ITT patients (B).